TAHP + AC + AHP

TAHP + AC + AHP appears to be a combination of agents referenced in the context of peptidomimetic inhibitors targeting the DR6/APP interaction. In particular, tAHP and AHP refer to peptidomimetic ligands designed to bind Death Receptor 6 (DR6), thereby blocking its interaction with amyloid precursor protein (APP). These agents are developed using structure-based drug design and d-retro-inverso modification for improved binding potency and pharmacokinetics. The most potent form described is a multi-arm polymer conjugate (PEG-tAHP-DRI), which demonstrates strong affinity for DR6, extended serum half-life, and significant inhibition of hematogenous tumor cell metastasis in preclinical models. The mechanism involves disruption of tumor cell attachment via blockade of DR6/APP interaction and reduction in necroptosis mediated by RIPK1 signaling[1].